{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Patients who had post-transplant complication (GVHD) as seen by clinical evidence including but not limited to skin rash, elevated liver function tests, nausea/vomiting/diarrhea.","groups":[{"description":"All patients received ATG 1mg/kg Day-16 and then 3.5 mg/kg Day -15 Fludarabine 30mg/m2/day on days -7 to -3 Busulfan 130 mg/m2 on days -4 \\& -3 Cyclophosphamide 1.5 g/m2 on day -2 Tacrolimus begins 0.03mg/kg bid on Day -1 Stem Cell transplant on Day 0 Methotrexate 5mg/m2 given D+1, +3 and +6","id":"OG000","title":"RIC Transplant Using ATG, Busulfan, Fludarabine and Cytoxan"}],"paramType":"NUMBER","populationDescription":"23 patients were able to be analyzed for severe gvhd","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"participants"}